Biogen (BIIB) PT Lowered to $343 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Biogen (BIIB) PT Lowered to $290 at Oppenheimer on CRL for MDD
August 7, 2023 6:28 AM EDTOppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $360.00) while maintaining a Outperform rating.
The analyst commented, "The MDD CRL for zuranolone deals BIIB a major blow but not a knockout. We expected BIIB to bolster topline growth... More
